FDA-cleared profile

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Clinical role
Detection, localization and characterization after the initial physician read
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Physician review of the complete examination and patient history remains necessary. Results are viewed after the initial read; this authorization does not replace clinical judgment or establish autonomous screening or DBT analysis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Standard DICOM FFDM mammograms from compatible systems; validation used standard four-view 2D images from Hologic, GE Healthcare and Siemens.
  • Who uses it?Intended users: Physicians interpreting screening mammograms
  • What does the software produce?Output: Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.
  • What is its most important limitation?Key limitation: Physician review of the complete examination and patient history remains necessary. Results are viewed after the initial read; this authorization does not replace clinical judgment or establish autonomous screening or DBT analysis.

Clinical takeaway. Clinical role: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Evidence takeaway. Evidence from the reviewed source record: The exact v1.1.10 standalone study is available with threshold and population context. Four stored family trial leads do not establish linkage to this release. The summary's AUC acceptance statement needs clarification.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Detection, localization and characterization after the initial physician read
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Standard DICOM FFDM mammograms from compatible systems; validation used standard four-view 2D images from Hologic, GE Healthcare and Siemens.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Female screening mammography; performance evaluated in adult women
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Physicians interpreting screening mammograms
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Physician review of the complete examination and patient history remains necessary. Results are viewed after the initial read; this authorization does not replace clinical judgment or establish autonomous screening or DBT analysis.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
The exact v1.1.10 standalone study is available with threshold and population context. Four stored family trial leads do not establish linkage to this release. The summary's AUC acceptance statement needs clarification.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact v1.1.10 standalone study is available with threshold and population context. Four stored family trial leads do not establish linkage to this release. The summary's AUC acceptance statement needs clarification.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
82.41% (95% CI 79.33-85.43%) at default operating point 0.1
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Standalone cancer detection in 2,412 adult female mammography cases from 28 US facilities; v1.1.10, not reader-aided sensitivity.

Reported specificity
81.54% (95% CI 79.78-83.31%) at default operating point 0.1
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Same standalone 2,412-case v1.1.10 study and radiologist/pathology-informed reference standard.

Standalone sensitivity

82.41 percent

  • EndpointDetection of breast cancer at default operating point 0.1
  • Population2,412 adult female FFDM cases from 28 US imaging facilities; radiologist adjudication using radiology/pathology records
  • Tested versionLunit INSIGHT MMG v1.1.10

Standalone specificity

81.54 percent

  • EndpointClassification of non-cancer cases at default operating point 0.1
  • Population2,412 adult female FFDM cases from 28 US imaging facilities; radiologist adjudication using radiology/pathology records
  • Tested versionLunit INSIGHT MMG v1.1.10

K260320 Lunit INSIGHT MMG v1.1.10 standalone validation

  • DesignManufacturer standalone evaluation on a held-out multi-facility US FFDM dataset
  • PopulationAdult female screening mammography cases, Hologic/GE/Siemens acquisitions; enriched validation composition is not a routine screening prevalence estimate
  • Scopeexact submission
  • Tested versionLunit INSIGHT MMG v1.1.10
  • Samplen=2412
  • Sites28
  • IndependenceSponsor or vendor study

K260320

Two or three breast radiologists defined truth using clinical and pathology evidence. Printed AUC lower bound 0.896 conflicts with the claimed greater-than-0.903 criterion; no independent reader benefit for this release is inferred.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Standard DICOM FFDM mammograms from compatible systems; validation used standard four-view 2D images from Hologic, GE Healthcare and Siemens.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · FDA 510(k) K260320: Lunit INSIGHT MMG v1.1.10

  2. Routing

    Source context, not route validation: DICOM mammograms are uploaded to the analysis engine; the summary identifies Secondary Capture analysis output and removal of its one-view mode.

    Scope: Exact FDA submission. Exact PACS interoperability and interface configuration need local confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · FDA 510(k) K260320: Lunit INSIGHT MMG v1.1.10

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Current hosting model, region, hardware, latency and retention for v1.1.10 were not established by the reviewed sources.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 ·

  4. Returned objects

    Source context, not route validation: Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · FDA 510(k) K260320: Lunit INSIGHT MMG v1.1.10

  5. Viewer/worklist/report

    Unresolved route: Color, single-color, grayscale or combined heatmaps of suspicious areas and an abnormality score for each breast. Version 1.1.10 updates the AI model and removes the one-view Secondary Capture output mode.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · FDA 510(k) K260320: Lunit INSIGHT MMG v1.1.10

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
DICOM mammograms are uploaded to the analysis engine; the summary identifies Secondary Capture analysis output and removal of its one-view mode.
  • Exact FDA submission
  • Checked 2026-09-05

Exact PACS interoperability and interface configuration need local confirmation.

Security
Lunit's information security page states the company is ISO/IEC 27001 certified, with ISO 13485 and MDSAP at its manufacturing site. Company-level; the page gives no scope, dates or product controls.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Vendor family commercial program

The current Lunit product page describes SecondRead AI as an optional out-of-pocket breast-screening analysis program with radiologist review, training and program materials.

product family · checked 2026-09-05

No exact v1.1.10 linkage, price or payer determination; regional availability requires confirmation.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260320
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Controlled catalog grouping. This submission supports FFDM; the grouping is not a DBT authorization claim.

Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-04-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
23Fields reviewed
12Source classes checked
0Screened PubMed leads
4Screened trial leads
0Unreviewed FDA recall leads

All four stored trial titles and sponsors were screened. They are plausible Lunit family leads but metadata does not identify v1.1.10/K260320; no trial result is promoted. Full registry content and release linkage remain pending. No stored PubMed candidates. The current discovery snapshot contains 0 PubMed and 4 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, vendor documentation, literature index, trial registry, fda decision summary, vendor product page, stored candidate metadata, stored recall candidates, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    The current vendor page mentions optional out-of-pocket SecondRead AI, but gives no verified v1.1.10 price, contract unit or included services.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Lunit INSIGHT MMG reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Search results were Korean coverage news, not US coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not verified - checked 2026-09-05 - Exact FDA submission

    Current hosting model, region, hardware, latency and retention for v1.1.10 were not established by the reviewed sources.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Vendor family program support mentions training, but the v1.1.10 curriculum, responsibilities and support term are not established.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Editorial acceptance question: verify the installed model, default operating point, supported FFDM systems and post-initial-read display sequence; supplied monitoring commitments remain unknown.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K260320: Lunit INSIGHT MMG v1.1.10

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinicalUse, modality, anatomy, implementationCapabilities, evidenceStudies, reportedSensitivity, reportedSpecificity

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Lunit INSIGHT MMG (v1.1.10) model card (K260320)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Lunit INSIGHT MMG: AI-powered software for 2D mammograms

    Lunit - Accessed 2026-09-05

    Scope: productFamily, implementationCapabilities, currentCommercialContext

  8. Lunit Information Security and Medical Device Registration

    Lunit - Accessed 2026-10-25

    Scope: security

Research history

  1. K260320 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-cleared K243341

Genius AI Detection 2.0

Hologic, Inc.

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-31
FDA-authorized DEN240047

Allix5

Clairity, Inc.

Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-05-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history